Cipla
Cipla Limited, a leading global pharmaceutical company headquartered in India, has been a pioneer in the healthcare industry since its establishment in 1935. With a strong presence in over 80 countries, Cipla focuses on developing a wide range of generic medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Renowned for its commitment to affordable healthcare, Cipla has made significant strides in areas such as respiratory, cardiovascular, and anti-retroviral therapies. The company is distinguished by its innovative approach to drug development and its robust pipeline of products, which cater to diverse therapeutic needs. Cipla's market position is bolstered by its extensive distribution network and strategic partnerships, making it a trusted name in the pharmaceutical sector. With numerous accolades for its contributions to global health, Cipla continues to lead the way in providing high-quality, accessible medicines.
DitchCarbon Score
How does Cipla's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cipla's score of 32 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cipla's reported carbon emissions
In 2023, Cipla reported significant carbon emissions, with Scope 1 emissions at approximately 35,831,000 kg CO2e, Scope 2 emissions at about 195,777,000 kg CO2e, and a staggering Scope 3 total of around 4,105,383,000 kg CO2e. This reflects the company's extensive operational footprint and highlights the importance of their climate commitments. Cipla has set ambitious targets to achieve carbon neutrality for its manufacturing operations in India by December 2025, focusing on both Scope 1 and Scope 2 emissions. The company aims to enhance energy efficiency and increase the use of renewable energy sources, including electricity and biofuels, as part of its long-term strategy. In previous years, Cipla's emissions have varied, with Scope 1 emissions recorded at about 41,617,000 kg CO2e in 2021 and 51,624,000 kg CO2e in 2020. Scope 2 emissions peaked at approximately 241,067,000 kg CO2e in 2020, demonstrating a need for ongoing reduction efforts. Cipla's commitment to reducing its carbon footprint is crucial in the pharmaceutical industry, where sustainability practices are increasingly vital for compliance and corporate responsibility. The company's proactive approach to climate action positions it as a leader in environmental stewardship within the sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 236,358,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 55,013,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cipla is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
